Safety Lead-In of the MEK Inhibitor Trametinib in Combination with GSK2141795, an AKT Inhibitor, in Patients with Recurrent Endometrial Cancer: An NRG Oncology/GOG Study

OBJECTIVE: We sought to determine safety and efficacy of the AKT inhibitor, GSK2141795, combined with the MEK inhibitor, trametinib, in endometrial cancer. METHODS: Patients with measurable recurrent endometrial cancer were eligible. One to two prior cytotoxic regimens were allowed; prior use of a M...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Gynecol Oncol
Autori principali: Westin, Shannon N., Sill, Michael W., Coleman, Robert L., Waggoner, Steven, Moore, Kathleen N., Mathews, Cara A., Martin, Lainie P., Modesitt, Susan C., Lee, Sanghoon, Ju, Zhenlin, Mills, Gordon B., Schilder, Russell J., Fracasso, Paula M., Birrer, Michael J., Aghajanian, Carol
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6922584/
https://ncbi.nlm.nih.gov/pubmed/31623857
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2019.09.024
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi